Adverum Biotechnologies Inc (ADVM)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Adverum Biotechnologies Inc chart...

About the Company

adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

CEO

Leone Patterson

Exchange

NASDAQ

Website

https://adverum.com/

$88M

Total Revenue

174

Employees

$170M

Market Capitalization

-1.33

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ADVM News

ADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023

on MSN ago, source:

ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the fourth quarter of 2023.More From InvestorPlace The #1 AI Investment Might Be This Company You’ve ...

Adverum Biotechnologies (ADVM) Receives a Buy from TD Cowen

9h ago, source:

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report). The ...

Adverum Biotechnologies: Q4 Earnings Snapshot

16h ago, source:

REDWOOD CITY, Calif. — REDWOOD CITY, Calif. — Adverum Biotechnologies Inc. (ADVM) on Monday reported a loss of $23.7 million in its fourth quarter. On a per-share basis, the Redwood City, ...

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

11h ago, source:

Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed ...

Adverum Biotechnologies Awaits Court Decision on Settlement

1mon ago, source: TipRanks on MSN

Adverum Biotechnologies (ADVM) has released an update. The Delaware Court of Chancery scheduled a hearing on April 9, 2024, to consider a proposed settlement in the stockholder derivative action ...

This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery

3d ago, source: 24/7 Wall St on MSN

With the pandemic largely in the rear-view mirror, vaccine maker Novavax has seen shares fall. Yet, analysts have high hopes ...

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

10d ago, source:

Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why ...

Stocks on the Launchpad: The Next 3 Market Sensations

20d ago, source:

In the current bullish stock market, it’s an exhilarating period for savvy investors betting on the upcoming market ...

Biotech VCs See Room for More Growth in Obesity Drug Market

11d ago, source:

Biotech VCs See Room for More Growth in Obesity Drug Market ...

Edwards Lifesciences Corporation

8mon ago, source:

View Edwards Lifesciences Corporation EW stock quote prices, financial information, real-time forecasts, and company news from CNN.

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

1mon ago, source:

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent ...

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

19d ago, source:

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...